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Abstract
Background: Previous cross-sectional studies have suggested that biomarkers of extracellular matrix remodelling are
associated with atrial fibrillation (AF), but no prospective data have yet been published. Hence, we examine whether plasma
matrix metalloproteinases (MMP) and their inhibitors are related to increased risk of incident AF.
Methods: We used a case-cohort design in the context of the prospective Atherosclerosis Risk in Communities (ARIC) study.
From 13718 eligible men and women free from AF in 1990-92, we selected a stratified random sample of 500 individuals
without and 580 with incident AF over a mean follow-up of 11.8 years. Using a weighted proportional hazards regression
model, the relationships between MMP-1, MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase (TIMP)-1, TIMP-2 and
C-terminal propeptide of collagen type-I with incident AF were examined after adjusting for confounders.
Results: In models adjusted for age, sex and race, all biomarkers were associated with AF, but only the relationship between
plasma MMP-9 remained significant in the fully-adjusted model: each one standard deviation increase in MMP-9 was
associated with 27% (95% Confidence Interval: 7% to 50%) increase in risk of AF with no evidence of an interaction with race
or sex. Individuals with above mean levels of MMP-9 were more likely to be male, white and current smokers.
Conclusions: The findings suggest that elevated levels of MMP-9 are independently associated with increased risk of AF.
However, given the lack of specificity of MMP-9 to atrial tissue, it remains to be determined whether the observed
relationship reflects the impact of atrial fibrosis or more generalized fibrosis on risk of incident AF.
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Introduction
The precise etiology of atrial fibrillation (AF) is unknown but
typically it is initiated by ectopic electrical activity that requires the
presence of an appropriate substrate, both structural and electrical,
to persist. Atrial fibrosis is considered to be a key element of the AF
substrate [1], with extracellular matrix (ECM) remodeling playing
a major role in this process. Biomarkers of ECM remodelling,
namely the matrix metalloproteinases (MMPs) and their specific
endogenous inhibitors (tissue inhibitors of matrix metalloprotei-
nases [TIMPs]), which are present in, but not exclusive to, the
human atrium [2] have been speculated to have an etiological role
in AF.
The MMPs are a relatively large family of twenty zinc-
dependent enzymes that together with TIMPs precisely regulate
the degradation of collagen and other ECM molecules in the atria.
Dysfunction in this finely regulated mechanism is postulated to
contribute to atherosclerotic plaque rupture and myocardial
infarction [3,4]. Some, but not all [5], prospective studies have
suggested that raised levels of MMPs may be modestly associated
with greater risk of coronary heart disease (CHD) while other
studies have suggested that MMPs and TIMPs are only correlates
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of inflammatory status and are not independently associated with
coronary risk [6]. To date, most of the evidence suggesting a
potential role of fibrosis and ECM remodelling in the etiology of
AF has come from animal or cross-sectional clinical studies. To the
best of our knowledge there are no prospective data that have
explored the relationship between biomarkers of ECM remodel-
ling and incident AF.
In this case-cohort study, we report on the associations between
several MMPs and their inhibitors and C-terminal propeptide of
collagen type-I (CICP)- a marker of collagen turnover, with risk of
incident AF in the Atherosclerosis Risk in Communities (ARIC)
study. The well-characterized nature of this cohort enabled
adjustment for a wide range of possible confounders- including
inflammatory markers, thereby allowing better estimation of the
underlying associations between biomarkers of ECM remodelling
and subsequent risk of AF.
Methods
The ARIC Study is a prospective cohort study of atherosclerotic
diseases within four communities in the United States: Forsyth
County, North Carolina; Jackson, Mississippi; Washington Coun-
ty, Maryland; and the northwest suburbs of Minneapolis,
Minnesota. The recruitment of study participants is described in
detail elsewhere [7]. The first examination took place during 1987-
89, with three follow-up visits taking place, each approximately
three years apart. Participants or their proxy were contacted
annually by telephone to ascertain information on hospitalizations
and deaths. Markers of ECM remodelling were measured in
stored serum samples obtained at Visit 2 (1990-92), and this was
considered the baseline for the present study.
Ethics Statement
The ARIC study has been approved by the Institutional Review
Boards (IRB) of all participating institutions, including the IRBs of
the University of Minnesota, Johns Hopkins University, University
of North Carolina, University of Mississippi Medical Center, and
Wake Forest University. All participants gave written informed
consent in each one of the study visits.
Case-Cohort Sample
This study utilized a case-cohort design to estimate the
associations between markers of fibrosis and AF. A case-cohort
study is an efficient approach to prospective studies in which
covariate information is collected in all cases and a representative
sample of the entire cohort (designated here as the subcohort) [8].
All individuals in ARIC for whom blood samples were available
and were free of AF at visit 2 were eligible for this study
(N = 13,718). Cases were those individuals who developed AF
between visit 2 (1990–1992) and December 31, 2008. Mean
duration of follow-up was 11.8 years (SD = 4.9). The subcohort
was comprised of individuals selected from a random sample of all
eligible ARIC study participants at visit 2. Sampling was stratified
by age (,57 or $57 years), sex and race (African-American or
white) to ensure an adequate number of subjects in each category.
Of the 1216 participants who were selected into this study, 136
were excluded due to missing measurements of biomarkers, or if
they were missing covariates. Among the remaining 1080
individuals, 568 people were in the random subcohort, 68 of
whom developed AF and hence, became part of the total of 580
with AF leaving 500 without the condition. A flowchart detailing
selection of cases and the random subcohort is shown in Figure 1.
Baseline Risk Factor Measurements
Baseline levels of biomarkers were obtained from frozen blood
serum samples that had been collected at visit 2 and stored at 270
degrees Celsius. Plasma levels of MMPs, TIMPs and CICP were
measured using commercially available assays (R&D Systems Inc.;
Minneapolis, Minnesota) in 2010. C-reactive protein (CRP) was
measured by the two-reagent, immunoturbidimetric system
(Roche Diagnostics, Inc). N-terminal pro-B-type natriuretic
peptide (NT-proBNP) was measured on the Roche Elecsys 2010
Analyzer (Roche Diagnostics Corporation) using a sandwich
immunoassay method (Roche Diagnostics, Indianapolis, IN
46250). The reliability coefficients, coefficients of variation and
the minimum detectable dose for each biomarker are shown in
Table S1.
Baseline measures of risk factors that were included as
covariates were taken at visit 2 according to standard protocol
[7]. Questionnaires were used to assess baseline educational level,
leisure time sports participation, use of antihypertensive and
diabetic medications, and histories of physician-diagnosed diabe-
tes, CHD or stroke. Education was dichotomized as high school
diploma or less, or more than high school. A sports index, ranging
from 1 (lowest) to 5 (highest), was derived from questionnaire items
on hours per week spent in up to four sports and the months per
year each sport was done [9]. Three blood pressure measurements
were taken with a random-zero sphygmomanometer with the
participant seated; the last two measurements were averaged.
Blood was drawn after an 8-h fasting period with minimal trauma
from an antecubital vein. Glucose was measured centrally by
standard enzymatic methods. The presence of diabetes at study
baseline (prevalent diabetes) was defined as a history of, or
treatment for, diabetes, a fasting glucose level of 126 mg/dl or
greater, or a casual blood glucose level of 200 mg/dl or greater. A
resting 12-lead electrocardiogram (ECG) was used to define the P–
R interval and presence of left ventricular hypertrophy (LVH).
ECG-diagnosed LVH was present if the Cornell voltage was
.28 mm in men or .22 mm in women [10]. Prevalent CHD at
baseline included a history of myocardial infarction (MI), MI
adjudicated from the baseline ECG, or history of coronary bypass
or angioplasty. Prevalent HF was identified using the Gothenburg
criteria, self-report of HF medication use in the past two weeks,
and incident HF between visits 1 and 2 [11,12].
Outcome Ascertainment
Diagnoses of incident AF and atrial flutter were obtained up to
December 2008 from three sources: ECGs done at study visits
(visits 2–4), presence of an International Classification of Disease
(ICD-9-CM) code for AF or atrial flutter (427.31 or 427.32) in a
hospital discharge, or AF listed as any cause of death on a death
certificate. Hospitalizations with AF associated with open cardiac
surgery were not considered events. Date of AF incidence was the
earliest of any AF diagnosis. All ARIC examination ECGs were
recorded using MAC PC Personal Cardiographs (Marquette
Electronics, Inc, Milwaukee, WI). A standard supine 12-lead
resting ECG was recorded at each clinic visit and was transmitted
by modem to the ARIC ECG Reading Center for automatic
reading and coding. All AF cases that were automatically detected
from the study ECGs were visually rechecked by a cardiologist
[13]. Prior analysis within the ARIC reported 84% sensitivity and
98% specificity in the ascertainment of AF events [14].
Statistical Analysis
Means and standard deviations (SDs) of continuous biomarkers
were calculated in cases and non-cases and compared using a
Student’s t-test. Hazard ratios were estimated using modified Cox
MMPs, ECM Remodelling and Atrial Bibrillation
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proportional hazard models that were weighted to take into
account the stratified case-cohort sampling design [8,15]. Robust
variance estimates were used to obtain 95% confidence intervals
with nominal coverage probability. Levels of biomarkers of ECM
remodelling were initially modeled as continuous variables to
compute standardized hazard ratios (i.e. per 1 SD increment).
Restricted cubic splines were used to assess whether the effect of
any of the indices deviated markedly from linearity. Linearity was
tested by assigning median values of each analyte according to
quintiles, and modeling this new variable as a continuous
covariate. The markers MMP-2 and CICP were not linear in
their respective associations, so CICP was log-transformed and
MMP-2 was modeled as a quadratic term in all subsequent
analysis and its association with AF reported by quintile. Model 1
adjusted for age (continuous), sex and race (African-American,
white). Model 2 additionally adjusted for study site, education
(high school degree vs. not), cigarette smoking (current vs. not),
body mass index, physical activity, diabetes (yes vs. no), systolic
blood pressure (continuous), diastolic blood pressure (continuous),
and use of antihypertensive medication (yes/no). Finally, Model 3
explored the impact of additional adjustment for CRP, NT-
proBNP, prevalent CHD, prevalent HF, and left ventricular
hypertrophy (LVH) on ECG (yes/no). A sensitivity analysis was
conducted after excluding those individuals (n = 10) in the cohort
sample with prevalent HF or prevalent CHD (n = 103). All
Figure 1. Flowchart of selection of cases and the random subcohort in the Atherosclerosis Risk in Communities Study.
doi:10.1371/journal.pone.0059052.g001
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statistical analyses were performed with SAS v 9.2 (SAS Inc, Cary,
NC). Reported p-values are two-tailed.
Results
In the current study population the crude incidence rate of AF
from baseline at visit 2 through to 2008 was 7.22 (95% CI: 6.86–
7.59). Individuals with incident AF were slightly older, with higher
levels of SBP and BMI, and a higher prevalence of diabetes,
prevalent CHD and LVH compared with those without AF.
Moreover, levels of MMP-1, MMP-9, TIMP-1 and NT-proBNP
were higher among those with AF compared with those without
the condition (Table 1).
Association between biomarkers of ECM remodelling and
incident AF
In models adjusted only for age, race and sex, several markers of
fibrosis were linearly associated with an increased risk of incident
AF (Table 2). Only the association between MMP-9 with incident
AF remained significant after inclusion of covariates in the model
with no evidence of any race or sex difference (Figure 2). Each one
standard deviation increment in MMP-9 increased the rate of AF
by 27% (95% CI: 7% to 50%) an association that remained
unchanged after exclusion of those individuals with prevalent HF
and CHD (n = 113; data not shown but available on request). For
MMP-2, there was some suggestion of a J-shape relation with risk
of AF in the base model, which was no longer apparent after
adjustment (Table 3).
Baseline characteristics of individuals in the cohort
sample according to level of MMP-9
A post-hoc comparison was performed in an attempt to
characterize individuals in the random cohort sample with an
MMP-9 (the only biomarker that was independently associated
with incident AF) value above and below the mean value
(271.5 ng/mL). In analyses that were adjusted for age, race, sex
education and weighted by the sampling fraction, those with
MMP-9 values above the mean were more likely to be male
(p = 0.02), white (p,0.0001), a current smoker (p = 0.0001) and to
have significantly higher levels of CRP (p = 0.005) and TIMP-1
(p = 0.0003) but lower levels of MMP-2 (p = 0.02) (Table 4). There
was no difference between the groups in the prevalence of the
remaining risk factors that included BMI, diabetes, BP, prevalent
HF, CHD and LVH, and NT-proBNP levels.
Table 1. Baseline characteristics (Visit 2) in the participants who developed atrial fibrillation (AF) during follow-up and those who
did not, ARIC, 1990–1992.
Baseline characteristics No AF (n = 500) AF (n = 580) p-value for difference
Mean (SD) Mean (SD)
Age (yr) 58.6 (5.4) 59.5 (5.6) 0.008
BMI (kg/m2) 28.4 (5.1) 29.8 (6.1) ,0.0001
SBP (mmHg) 123.7 (19.0) 128.7 (20.9) ,0.0001
DBP (mmHg) 73.3 (9.8) 73.7 (11.7) 0.53
C-reactive protein, mg/L 5.0 (8.8) 5.8 (10.5) 0.15
Physical activity 2.4 (0.8) 2.4 (0.8) 0.73
NT-proBNP, pg/mL 110.1 (506.4) 224.7 (1103.2) 0.03
MMP-1 (ng/mL) 7.4 (5.0) 8.1 (5.8) 0.05
MMP-2 (ng/mL) 171.8 (29.8) 173.2 (29.8) 0.44
MMP-9 (ng/mL) 270.3 (144.8) 312.6 (173.6) ,0.0001
TIMP-1 (ng/mL) 160.3 (40.3) 168.7 (41.4) 0.0007
TIMP-2 (ng/mL) 83.0 (14.9) 84.0 (14.4) 0.27
CICP (ng/mL) 3.6 (3.3) 3.8 (3.1) 0.34
% No. (%) No. (%) p-value for difference
Female 231 (46.2) 242 (41.7) 0.14
African-American 214 (42.8) 225 (38.8) 0.18
High school degree 355 (71.0) 396 (68.3) 0.33
Current smoker 103 (21.8) 144 (24.8) 0.24
Diabetes mellitus 82 (16.4) 163 (28.1) ,0.0001
Prevalent HF 2 (0.4) 8 (1.4) 0.09
Prevalent CHD 29 (5.8) 79 (13.6) ,0.0001
Hypertension medication 172 (34.4) 306 (52.8) ,0.0001
Left ventricular hypertrophy 10 (2.0) 35 (6.0) 0.0009
Values correspond to mean (SD) or number (%). BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; NT-proBNP = N-terminal pro-B-
type natriuretic peptide; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase; CIC = C-terminal propeptide of collagen; HF = heart failure;
CHD = coronary heart disease.
doi:10.1371/journal.pone.0059052.t001
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Figure 2. Association between quartiles of plasma matrix metalloproteinase-9 with incident atrial fibrillation in the Atherosclerosis
Risk in Communities Study. The model is adjusted for age, sex, race, study site, education (high school degree vs. not), smoking (current vs. not),
body mass index, physical activity, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein,
NT-proBNP, prevalent coronary heart disease, prevalent heart failure and left ventricular hypertrophy.
doi:10.1371/journal.pone.0059052.g002
Table 2. Hazard ratio (95% confidence interval) of atrial fibrillation by markers of atrial ECM remodelling, ARIC, 1990–2007.
HR 95%CI P-value P-value for race interaction P-value for sex interaction
MMP-1 Model 1 1.10 (0.97–1.24) 0.15
Model 2 1.10 (0.97–1.26) 0.15
Model 3 1.09 (0.95–1.25) 0.21 0.39 0.13
MMP-9 Model 1 1.37 (1.20–1.58) ,0.0001
Model 2 1.28 (1.09–1.51) 0.002
Model 3 1.27 (1.07–1.50) 0.006 0.66 0.94
TIMP-1 Model 1 1.38 (1.17–1.63) ,0.0001
Model 2 1.24 (1.05–1.47) 0.01
Model 3 1.17 (0.97–1.41) 0.10 0.33 0.54
TIMP-2 Model 1 1.13 (0.98–1.29) 0.08
Model 2 1.13 (0.98–1.30) 0.10
Model 3 1.07 (0.92–1.24) 0.39 0.64 0.17
CICP * Model 1 1.23 (1.08–1.41) 0.003
Model 2 1.18 (1.03–1.36) 0.02
Model 3 1.05 (0.89–1.24) 0.58 0.42 0.65
Per standard deviation, unless otherwise noted. MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase; CICP = C-terminal propeptide of
collagen; *CICP is log-transformed. Model 1: Cox proportional hazard model adjusted for age, sex and race. Model 2: Model 1+study site, education (high school degree
vs. not), smoking (current vs. not), body mass index, physical activity, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, and diabetes.
Model 3: Model 2+C-reactive protein, NT-proBNP, prevalent coronary heart disease, prevalent heart failure and left ventricular hypertrophy.
doi:10.1371/journal.pone.0059052.t002
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Discussion
Findings from this prospective community-based study provide
the first evidence to suggest that a higher circulating level of
plasma MMP-9 is an independent risk factor for incident AF. This
finding adds to the growing body of clinical and epidemiological
evidence to suggest that elevated levels of this biomarker are
associated with an increasing number of cardiac and vascular
disorders including acute coronary syndromes, cerebrovascular
disease, atherosclerosis and abdominal aortic aneurysm [16–20].
The magnitude of the association was of the order of about one-
quarter greater risk in AF per standard deviation increment in
MMP-9, with no evidence of any difference by race or sex. After
adjusting for covariates the relationship remained robust but the
possibility of residual confounding by some unknown factors could
not be precluded. Although several of the other biomarkers that
were investigated were positively associated with incident AF in
the baseline models, these associations were attenuated and non-
significant once the effect of covariates was considered.
The epidemiological case for a role of MMP-9 in the
pathogenesis of AF and other cardiac abnormalities is growing:
MMP-9 in particular, has been shown to have a key role in
ischemia-reperfusion-induced myocardial matrix remodeling [21–
23]. Higher plasma levels of MMP-9 have been shown to correlate
with increased MMP-9 activity [24]. In addition, compared with
individuals with normal sinus rhythm, those with AF have been
shown to have higher levels of the active form of MMP-9 in atrial
tissue whereas there was no difference between these two groups in
the levels of MMP-1 and MMP-2 [2]. MMP-9 has also been
reported to be associated with inflammatory changes and is
associated with atherosclerotic plaque vulnerability [25–27].
Table 3. The relationship between MMP-2 and incident atrial
fibrillation modeled by quintiles, ARIC 1990–2007.
Hazard ratio (95% CI) P-value
Model 1: ,150 (ng/mL) (Ref)
150–162 0.69 (0.47–1.02) 0.06
163–174 0.66 (0.45–0.97) 0.04
175–189 0.74 (0.50–1.09) 0.13
190+ 1.07 (0.73–1.56) 0.74
Model 3: ,150 (ng/mL) (Ref)
150–162 0.78 (0.51–1.18) 0.24
163–174 0.72 (0.47–1.10) 0.13
175–189 0.80 (0.53–1.20) 0.28
190+ 1.02 (0.66–1.57) 0.93
Conventions as in Table 2.
doi:10.1371/journal.pone.0059052.t003
Table 4. Baseline characteristics of individuals dichotomized by whether they had above or below the mean value (271.5 ng/mL)
of MMP-9 in the cohort random sample (n = 580).
Characteristics MMP-9#271.5 ng/mL (n = 342) MMP-9.271.5 ng/mL (n = 226) p-value for difference
Mean (SD) Mean (SD)
Age (yr) 58.7 (5.3) 58.5 (5.4) 0.40
BMI (kg/m2) 28.8 (5.3) 27.8 (4.9) 0.93
Physical activity 2.5 (0.7) 2.4 (0.8) 0.30
SBP (mmHg) 124.9 (20.4) 121.7 (16.5) 0.15
DBP (mmHg) 73.8 (9.9) 72.4 (9.6) 0.21
C-reactive protein, mg/L 4.1 (5.6) 6.4 (12.1) 0.005
NT-proBNP, pg/mL 128.9 (642.7) 80.5 (93.7) 0.86
MMP-1 (ng/mL) 7.1 (4.7) 7.9 (5.4) 0.07
MMP-2 (ng/mL) 175.2 (31.3) 166.4 (26.4) 0.02
TIMP-1 (ng/mL) 155.1 (43.4) 168.4 (33.2) 0.0003
TIMP-2 (ng/mL) 83.9 (16.4) 81.6 (12.2) 0.81
CICP (ng/mL) 3.8 (4.2) 3.3 (1.0) 0.16
% % %
Female 51.6 37.6 0.02
African-American 52.0 28.4 ,0.0001
Current smoker 15.0 32.5 0.0001
Diabetes mellitus 18.0 13.9 0.85
Prevalent HF 0.3 0.5 0.40
Prevalent CHD 5.9 5.7 0.62
Hypertension medication 36.0 32.0 0.24
Left ventricular hypertrophy 2.6 1.0 0.49
High school degree 69.6 73.2 0.33
*Models to determine p-value are adjusted for age, race, sex, education and the sampling fraction (weights). BMI = body mass index; SBP = systolic blood pressure;
DBP = diastolic blood pressure; NT-proBNP = N-terminal pro-B-type natriuretic peptide; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix
metalloproteinase; CICP = C-terminal propeptide of collagen; HF = heart failure; CHD = coronary heart disease.
doi:10.1371/journal.pone.0059052.t004
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Furthermore, more recent data from the Dallas Heart Study
showed that higher MMP-9 levels were independently associated
with greater aortic wall thickness and larger luminal diameter
supporting the hypothesis that MMP-9 is linked to cardiac
structure and pathology [28].
This is the first report of the prospective relationship between
markers of ECM remodelling and risk of incident AF. Previous
studies have published on the relationship between markers of
ECM remodelling with CHD [5,6,29], but the results have been
inconsistent with studies reporting either a positive or null effect
while others have shown that markers of inflammation largely
confound the association. In a publication from the ARIC group,
plasma levels of TIMP-1 and MMP-1 were unrelated to increased
risk of coronary artery disease [5] whereas in Framingham, plasma
TIMP-1 levels were positively associated with cardiovascular
incidence and death [29]. In contrast, data from the British
Regional Heart Study suggested a positive relationship between
MMP-9 with incident CHD that, however, was not independent
of the effects and markers of generalized inflammation [6]. A
possible explanation for these discrepant findings may be due to
differences in how the biomarkers were sourced and stored. For
example, the level of MMP-9 has been shown to be higher in
serum than in plasma [30] as well as in samples treated with the
anticoagulant EDTA as compared with lithium heparin or citrate
[31].
Most evidence regarding atrial fibrosis and AF has come from
cross-sectional and case-control studies. Early cardiac biopsy
studies showed that compared with subjects with normal sinus
rhythm individuals with AF have higher levels of collagen
deposition in the atria [32] and greater expression of MMP-9
[2]. Case-control studies of genetic polymorphisms that alter
MMP-9 production and function have also provided some support
for a role of MMP-9 in the etiology of AF [33,34]. Further, there
are data to suggest that levels of MMPs and TIMPs may differ
according to the whether the individual has paroxysmal or
persistent AF [35]. For example, patients with persistent AF were
reported to have significantly higher levels of serum CICP, TIMP-
1 but lower MMP-1 levels compared with those with paroxysmal
AF suggesting that the degree of atrial remodeling is due in part to
the type of AF: a recent study reported higher MMP-9 levels in
patients with permanent AF compared with with paroxysmal AF
[36]. Previous studies have also suggested that levels of MMP-9 are
higher among those with hypertension [37] whereas in the current
study, there was no evidence to support this. Rather, we observed
that those individuals with above mean values of MMP-9 were
more likely to be male, white and smokers similar to data from the
Dallas Heart Study and the British Heart Study [6,28].
There are several limitations of this current study: first, although
studies have confirmed the presence of MMP-1, MMP-2, and
MMP-9 in human atrial tissue [2], these biomarkers of ECM
remodelling are not confined to the myocardium and therefore we
were unable to determine whether the observed relationship
between MMP-9 and incident AF is due to atrial fibrosis or more
generalized fibrosis. Possible future studies that utilize a Mendelian
randomization study design to explore the effect of genetic variants
that influence MMP-9 levels on subsequent risk of AF would
provide useful information as to the casual nature of the
relationship. Such an approach would also minimize the impact
that residual confounding may have had on the observed
association between MMP-9 and incident AF observed in the
current study. But even if a causal relation could be demonstrated,
the clinical significance is likely to be limited given the relatively
weak association between MMP-9 and subsequent risk of AF.
Second, we had no information regarding the subtypes of AF that
were sustained (i.e. paroxysmal, persistent, or permanent), and
therefore we were unable to examine whether there were any
differences in the relationships between the biomarkers and AF
subtype. Third, the generalizability of these data is restricted to US
blacks and whites and further studies from other countries are
warranted to confirm the current findings in other population
groups. Furthermore, as cases of AF were mainly ascertained
through hospital discharge codes, this may have led to under-
ascertainment of events that perhaps, were not severe enough to
warrant hospitalization. Fourth, the biomarkers of ECM remod-
elling had been frozen at 270 degrees C for up to two decades
prior to the assays and the degree of degradation of these samples
is unknown. However, previous work on the stability of other
analytes (HbA1c) stored in similar conditions in the ARIC cohort
suggest that measurements from long-term stored samples are
strongly correlated with values obtained prior to long-term storage
(r = 0.97) [38]. We cannot exclude that our findings represent an
epiphenomenon, rather than a biologically important association.
These results need to be replicated in additional cohorts. Finally,
future studies that examine the interplay between MMP-9 and
other biomarkers of AF including NT-proBNP would provide
useful insight into the etiology of AF.
Conclusions
In summary, findings from this community-based study provide
the first prospective data suggesting an independent relationship
between MMP-9 and subsequent risk of AF. These data require
verification from future cohort studies that are able to assess the
specificity of MMP-9 to AF (as opposed to other forms of cardiac
arrhythmia) as well as the role, if any, MMPs may play in the
initiation and perpetuation of AF and other major cardiac and
vascular disorders.
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